Actelion snags lymphoma drug in $250M buyout deal for Ceptaris

John Carroll

Switzerland's has struck a to buy Malvern, PA-based Therapeutics for $ 250 million–provided the FDA comes through with an approval of its T-cell .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS